<DOC>
	<DOCNO>NCT00540696</DOCNO>
	<brief_summary>The purpose study develop functional capacity screen tool ( FCST ) estimate baseline functional capacity anemic subject nonmyeloid malignancy receive multicycle chemotherapy . Sites randomly assign 1:1 ratio 1 2 different subject-reported functional capacity questionnaire . The questionnaire use develop FCST . Subjects participate Modified Harvard Step Test ( MHST ) require timepoints receive darbepoetin alfa every 2 week 15 week . All subject return follow-up visit 2 week last dose darbepoetin alfa .</brief_summary>
	<brief_title>Study Develop Screening Tool Functional Capacity Anemic Subjects With Nonmyeloid Malignancies Receiving Chemotherapy Darbepoetin Alfa</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Nonmyeloid malignancy Anemia ( hgb less equal 11.0 g/dL ) relate cancer chemotherapy Plan receive cyclic chemotherapy additional 8 week Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Adequate renal liver function Ability participate MHST base clinical judgement investigator At least 18 year age Iron deficiency Received recombinant human erythropoietin ( rHuEPO ) therapy within 4 week prior enrollment Unstable cardiac disease Current active condition create clinical danger subject participate MHST know positive test HIV infection Previous hematologic disorder associate anemia Currently receive betablockers Use drug device approve FDA indication Pregnant breast feed Known hypersensitivity recombinant mammalianderived product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Anemia</keyword>
	<keyword>Non-Myeloid Malignancies</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>chemotherapy</keyword>
</DOC>